The National Institutes of Health offers a grant for the Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain. The grant aims to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain management. Applicants are required to have a promising hit/lead, strong biological rationale, and assays for optimization. The program covers optimization, early development, IND-enabling studies, and assembly of IND application. It is a milestone-driven cooperative agreement program with active NIH program staff involvement. Closing date for applications is Jun 04, 2019.
Opportunity ID: 310969
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-19-020 |
| Funding Opportunity Title: | HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain – (U44 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Food and Nutrition Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Dec 10, 2018 |
| Last Updated Date: | Mar 07, 2019 |
| Original Closing Date for Applications: | Mar 06, 2019 |
| Current Closing Date for Applications: | Jun 04, 2019 |
| Archive Date: | Jul 04, 2019 |
| Estimated Total Program Funding: | $6,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-020.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Extended Expiration Date as per the notice NOT-NS-19-042 | Mar 07, 2019 | |
| Mar 07, 2019 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-19-020 |
| Funding Opportunity Title: | HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain – (U44 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Food and Nutrition Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Dec 10, 2018 |
| Last Updated Date: | Mar 07, 2019 |
| Original Closing Date for Applications: | Mar 06, 2019 |
| Current Closing Date for Applications: | Jun 04, 2019 |
| Archive Date: | Jul 04, 2019 |
| Estimated Total Program Funding: | $6,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-020.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-19-020 |
| Funding Opportunity Title: | HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain – (U44 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Food and Nutrition Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 07, 2019 |
| Last Updated Date: | Dec 10, 2018 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Mar 06, 2019 |
| Archive Date: | Apr 11, 2019 |
| Estimated Total Program Funding: | $6,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-020.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | FORMS-E | PKG00246775 | Dec 09, 2018 | Jun 04, 2019 | View |
Package 1
Mandatory forms
310969 RR_SF424_2_0-2.0.pdf
310969 PHS398_CoverPageSupplement_4_0-4.0.pdf
310969 RR_OtherProjectInfo_1_4-1.4.pdf
310969 PerformanceSite_2_0-2.0.pdf
310969 RR_KeyPersonExpanded_2_0-2.0.pdf
310969 RR_Budget_1_4-1.4.pdf
310969 PHS398_ResearchPlan_4_0-4.0.pdf
310969 SBIR_STTR_Information_1_2-1.2.pdf
Optional forms
310969 RR_SubawardBudget30_1_4-1.4.pdf
310969 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
